Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo

Molecular Therapy

Volumn 20, Issue 3, 2012, Pages 644-651

  Qu, Yanyan ^a   Chen, Lu ^a   Lowe, Devin B ^a   Storkus, Walter J ^a,b   Taylor, Jennifer L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12P70; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBET; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PERICYTE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

MUS;

EID: 84857786740     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.283     Document Type: Article

References (48)

1. Palucka, K, Ueno, H and Banchereau, J (2011). Recent developments in cancer vaccines. J Immunol 186: 1325-1331.
2. Kalinski, P (2009). Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs 10: 526-535.
3. Gilboa, E (2007). DC-based cancer vaccines. J Clin Invest 117: 1195-1203. (Pubitemid 46718404)
4. Jandus, C, Speiser, D and Romero, P (2009). Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res 22: 711-723.
5. Vujanovic, L and Butterfield, LH (2007). Melanoma cancer vaccines and anti-tumor T cell responses. J Cell Biochem 102: 301-310. (Pubitemid 47519404)
6. Bose, A, Taylor, JL, Alber, S, Watkins, SC, Garcia, JA, Rini, BI et al. (2011). Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129: 2158-2170.
7. Dobrzanski, MJ, Reome, JB and Dutton, RW (1999). Therapeutic effects of tumorreactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 162: 6671-6680. (Pubitemid 29309392)
8. Dudley, ME, Gross, CA, Langhan, MM, Garcia, MR, Sherry, RM, Yang, JC et al. (2010). CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16: 6122-6131.
9. Kapsenberg, ML, Hilkens, CM, Wierenga, EA and Kalinski, P (1999). The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Clin Exp Allergy 29 (suppl. 2): 33-36. (Pubitemid 29314660)
10. Mailliard, RB, Wankowicz-Kalinska, A, Cai, Q, Wesa, A, Hilkens, CM, Kapsenberg, ML et al. (2004). alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64: 5934-5937. (Pubitemid 39129387)
11. Tada, H, Aiba, S, Shibata, K, Ohteki, T and Takada, H (2005). Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73: 7967-7976. (Pubitemid 41740282)
12. Napolitani, G, Rinaldi, A, Bertoni, F, Sallusto, F and Lanzavecchia, A (2005). Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776. (Pubitemid 43090462)
13. Tatsumi, T, Huang, J, Gooding, WE, Gambotto, A, Robbins, PD, Vujanovic, NL et al. (2003). Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 63: 6378-6386. (Pubitemid 37255187)
14. Lipscomb, MW, Chen, L, Taylor, JL, Goldbach, C, Watkins, SC, Kalinski, P et al. (2009). Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. J Immunol 183: 7250-7258.
15. Qu, Y, Chen, L, Pardee, AD, Taylor, JL, Wesa, AK and Storkus, WJ (2010). Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol 185: 2895-2902.
16. Yao, Y, Li, W, Kaplan, MH and Chang, CH (2005). Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 201: 1899-1903. (Pubitemid 41002926)
17. Komita, H, Zhao, X, Taylor, JL, Sparvero, LJ, Amoscato, AA, Alber, S et al. (2008). CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Res 68: 8076-8084.
18. Tüting, T, Gambotto, A, DeLeo, A, Lotze, MT, Robbins, PD and Storkus, WJ (1999). Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 6: 73-80. (Pubitemid 129667761)
19. Feijoó, E, Alfaro, C, Mazzolini, G, Serra, P, Peñuelas, I, Arina, A et al. (2005). Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 116: 275-281. (Pubitemid 40967265)
20. Lugo-Villarino, G, Maldonado-Lopez, R, Possemato, R, Penaranda, C and Glimcher, LH (2003). T-bet is required for optimal production of IFN-αand antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci USA 100: 7749-7754. (Pubitemid 36760041)
21. Esensten, JH, Lee, MR, Glimcher, LH and Bluestone, JA (2009). T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol 183: 75-82.
22. Wang, J, Fathman, JW, Lugo-Villarino, G, Scimone, L, von Andrian, U, Dorfman, DM et al. (2006). Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J Clin Invest 116: 414-421. (Pubitemid 43228358)
23. Heckman, KL, Radhakrishnan, S, Peikert, T, Iijima, K, McGregor, HC, Bell, MP et al. (2008). T-bet expression by dendritic cells is required for the repolarization of allergic airway inflammation. Eur J Immunol 38: 2464-2474.
24. Lugo-Villarino, G, Ito, S, Klinman, DM and Glimcher, LH (2005). The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells. Proc Natl Acad Sci USA 102: 13248-13253. (Pubitemid 41325009)
25. Yu, HR, Chen, RF, Hong, KC, Bong, CN, Lee, WI, Kuo, HC et al. (2005). IL-12-independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus. Eur J Immunol 35: 3664-3672.
26. Cousens, LP, Peterson, R, Hsu, S, Dorner, A, Altman, JD, Ahmed, R et al. (1999). Two roads diverged: interferon alpha/beta-and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J Exp Med 189: 1315-1328.
27. Osaki, T, Péron, JM, Cai, Q, Okamura, H, Robbins, PD, Kurimoto, M et al. (1998). IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma-and IL-12-independent antitumor effects. J Immunol 160: 1742-1749. (Pubitemid 28106460)
28. Chiaramonte, MG, Hesse, M, Cheever, AW and Wynn, TA (2000). CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosomeegg-induced pathology by an IL-12-independent mechanism. J Immunol 164: 973-985. (Pubitemid 30043725)
29. Skokos, D and Nussenzweig, MC (2007). CD8-DCs induce IL-12-independent Th1 differentiation through Delta 4 Notch-like ligand in response to bacterial LPS. J Exp Med 204: 1525-1531. (Pubitemid 47048020)
30. Soares, H, Waechter, H, Glaichenhaus, N, Mougneau, E, Yagita, H, Mizenina, O et al. (2007). A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med 204: 1095-1106. (Pubitemid 46798153)
31. Kondoh, K, Sunadome, K and Nishida, E (2007). Notch signaling suppresses p38 MAPK activity via induction of MKP-1 in myogenesis. J Biol Chem 282: 3058-3065. (Pubitemid 47084350)
32. Wang, S, Yang, J, Qian, J, Wezeman, M, Kwak, LW and Yi, Q (2006). Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107: 2432-2439. (Pubitemid 43345564)
33. Zhao, F, Falk, C, Osen, W, Kato, M, Schadendorf, D and Umansky, V (2009). Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 15: 4382-4390.
34. Jarnicki, AG, Conroy, H, Brereton, C, Donnelly, G, Toomey, D, Walsh, K et al. (2008). Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 180: 3797-3806.
35. Pilette, C, Detry, B, Guisset, A, Gabriels, J and Sibille, Y (2010). Induction of interleukin-10 expression through Fcalpha receptor in human monocytes and monocyte-derived dendritic cells: role of p38 MAPKinase. Immunol Cell Biol 88: 486-493.
36. Wang, S, Hong, S, Yang, J, Qian, J, Zhang, X, Shpall, E et al. (2006). Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108: 4071-4077. (Pubitemid 44913277)
37. Kikuchi, T, Moore, MA and Crystal, RG (2000). Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96: 91-99. (Pubitemid 30456456)
38. Kuwashima, N, Nishimura, F, Eguchi, J, Sato, H, Hatano, M, Tsugawa, T et al. (2005). Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 175: 2730-2740. (Pubitemid 41113890)
39. Pilon-Thomas, S, Mackay, A, Vohra, N and Mulé, JJ (2010). Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 184: 3442-3449.
40. Koike, N, Pilon-Thomas, S and Mulé, JJ (2008). Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother 31: 402-412. (Pubitemid 351595163)
41. Pilon-Thomas, S, Li, W, Briggs, JJ, Djeu, J, Mulé, JJ and Riker, AI (2006). Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29: 381-387. (Pubitemid 44288950)
42. Shimizu, K, Fields, RC, Redman, BG, Giedlin, M and Mulé, JJ (2000). Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Cancer J Sci Am 6 (suppl. 1): S67-S75.
43. Saji, H, Song, W, Furumoto, K, Kato, H and Engleman, EG (2006). Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 12: 2568-2574.
44. Matsushita, N, Komine, H, Grolleau-Julius, A, Pilon-Thomas, S and Mulé, JJ (2010). Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity. Cancer Immunol Immunother 59: 875-884.
45. Fourcade, J, Sun, Z, Benallaoua, M, Guillaume, P, Luescher, IF, Sander, C et al. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207: 2175-2186.
46. Quezada, SA, Peggs, KS, Curran, MA and Allison, JP (2006). CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935-1945. (Pubitemid 44033317)
47. Zhao, X, Bose, A, Komita, H, Taylor, JL, Kawabe, M, Chi, N et al. (2011). Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumorassociated stromal antigens. Mol Ther 19: 805-814.
48. Huang, AY, Gulden, PH, Woods, AS, Thomas, MC, Tong, CD, Wang, W et al. (1996). The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93: 9730-9735. (Pubitemid 26296677)